In the QBB cohort, about 45% of the 24 MODY cases had these mutations [13]; however, at the time of data collection, these individuals were misdiagnosed as T2D and were on standard T2D medication (metformin) and did not receive proper treatment plans designated for individuals with HNF1A and HNF4A mutations. The gene discussed is HNF1A; the disease is type 2 diabetes mellitus.